ALB Stock Analysis: Albemarle | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 13.989m USD | 12M Return: 57.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 273M
Qual. Beats: 1
Rev. Trend: -91.7%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Albemarle Corporation (NYSE: ALB) is a U.S.-based specialty chemicals producer headquartered in Charlotte, North Carolina, operating through three segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment supplies lithium compounds such as lithium carbonate, lithium hydroxide, and lithium chloride used primarily in batteries for electric vehicles, consumer electronics, and grid and solar energy storage. The Specialties segment produces bromine-based chemicals, specialty lithium products (including butyllithium and lithium aluminum hydride), cesium, zirconium, barium, and titanium compounds for industries including fire safety, pharmaceuticals, and pyrotechnics. The Ketjen segment provides hydroprocessing, fluidized catalytic cracking, and alkylation catalysts used in petroleum refining, along with organometallic and curative catalyst solutions.
Albemarle serves a diverse end-market base spanning grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture, food, and pharmaceuticals. The company is classified within the Materials sector under the Specialty Chemicals sub-industry, and as one of the worlds largest integrated lithium producers, its earnings are closely tied to lithium pricing cycles and EV battery demand growth. Founded in 1887, Albemarle has a long operational history in industrial and fine chemicals.
- Lithium prices slide on weakening EV demand
- Energy Storage margins compress amid oversupply
- Specialties bromine business delivers stable cash flow
| Net Income: -232.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 4.73 > 1.0 |
| NWC/Revenue: 30.63% < 20% (prev 42.46%; Δ -11.83% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.08b > Net Income -232.9m |
| Net Debt (895.1m) to EBITDA (747.1m): 1.20 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.6m) vs 12m ago 0.85% < -2% |
| Gross Margin: 18.53% > 18% (prev 3.49%; Δ 15.04% > 0.5%) |
| Asset Turnover: 34.19% > 50% (prev 29.96%; Δ 4.23% > 0%) |
| Interest Coverage Ratio: 0.48 > 6 (EBIT TTM 92.3m / Interest Expense TTM 191.8m) |
| A: 0.11 (Total Current Assets 3.26b - Total Current Liabilities 1.58b) / Total Assets 15.1b |
| B: 0.32 (Retained Earnings 4.84b / Total Assets 15.1b) |
| C: 0.01 (EBIT TTM 92.3m / Avg Total Assets 16.1b) |
| D: 1.96 (Book Value of Equity 9.85b / Total Liabilities 5.03b) |
| Altman-Z'' = 3.87 = AA |
| DSRI: 0.76 (Receivables 659.5m/807.9m, Revenue 5.49b/5.09b) |
| GMI: 0.19 (GM 3.49% / 18.53%) |
| AQI: 1.05 (AQ_t 0.22 / AQ_t-1 0.21) |
| SGI: 1.08 (Revenue 5.49b / 5.09b) |
| TATA: -0.09 (NI -232.9m - CFO 1.08b) / TA 15.1b) |
| Beneish M = -3.88 (Cap -4..+1) = AAA |
As of July 29, 2026, the stock is trading at USD 116.18 with a total of 1,463,658 shares traded. Over the past week, the price has changed by -1.71%, over one month by -10.44%, over three months by -41.62% and over the past year by +57.49%.
Current recommended Stop Loss: 107.70 (which is 7.3% or 1.4 ATR below the current price).
Albemarle has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold ALB.
- StrongBuy: 6
- Buy: 3
- Hold: 17
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 196.4 | 69.1% |
P/E Forward = 12.3609
P/S = 2.546
P/B = 1.8306
P/EG = 0.7941
Revenue TTM = 5.49b USD
EBIT TTM = 92.3m USD
EBITDA TTM = 747.1m USD
Long Term Debt = 1.81b USD (from longTermDebt, last quarter)
Short Term Debt = 74.6m USD (from shortTermDebt, last quarter)
Debt = 1.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 103.1m
Net Debt = 895.1m USD (calculated: Debt 1.98b - CCE 1.09b)
Enterprise Value = 14.9b USD (14.0b + Debt 1.98b - CCE 1.09b)
Interest Coverage Ratio = 0.48 (Ebit TTM 92.3m / Interest Expense TTM 191.8m)
EV/FCF = 25.78x (Enterprise Value 14.9b / FCF TTM 577.3m)
FCF Yield = 3.88% (FCF TTM 577.3m / Enterprise Value 14.9b)
FCF Margin = 10.51% (FCF TTM 577.3m / Revenue TTM 5.49b)
Net Margin = -4.24% (Net Income TTM -232.9m / Revenue TTM 5.49b)
Gross Margin = 18.53% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.48b) / Revenue TTM)
Gross Margin QoQ = 35.06% (prev 14.20%)
Tobins Q-Ratio = 0.98 (Enterprise Value 14.9b / Total Assets 15.1b)
Interest Expense / Debt = 9.66% (Interest Expense 191.8m / Debt 1.98b)
Taxrate = 8.46% (21.5m / 254.2m)
NOPAT = 84.5m (EBIT 92.3m * (1 - 8.46%))
Current Ratio = 2.07 (Total Current Assets 3.26b / Total Current Liabilities 1.58b)
Debt / Equity = 0.20 (Debt 1.98b / totalStockholderEquity, last quarter 9.85b)
Debt / EBITDA = 1.20 (Net Debt 895.1m / EBITDA 747.1m)
Debt / FCF = 1.55 (Net Debt 895.1m / FCF TTM 577.3m)
Total Stockholder Equity = 9.91b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.45% (Net Income -232.9m / Total Assets 15.1b)
RoE = -2.35% (Net Income TTM -232.9m / Total Stockholder Equity 9.91b)
RoCE = 0.79% (EBIT 92.3m / Capital Employed (Equity 9.91b + L.T.Debt 1.81b))
RoIC = 0.63% (NOPAT 84.5m / Invested Capital 13.4b)
WACC = 12.77% (E(14.0b)/V(16.0b) * Re(13.33%) + D(1.98b)/V(16.0b) * Rd(9.66%) * (1-Tc(0.08)))
Discount Rate = 13.33% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 74.93 | Cagr: 0.47%
[DCF] Terminal Value 61.59% ; FCFF base≈577.3m ; Y1≈579.7m ; Y5≈614.0m
[DCF] Fair Price = 38.65 (EV 5.45b - Net Debt 895.1m = Equity 4.56b / Shares 117.9m; r=12.77% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.46 | # QB: 1
Revenue Correlation: -91.69 | Revenue CAGR: -25.11% | SUE: 1.30 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.21 | Chg30d=+4.24% | Revisions=+44% | Analysts=16
EPS next Quarter (2026-09-30): EPS=3.51 | Chg30d=+3.33% | Revisions=+38% | Analysts=15
EPS current Year (2026-12-31): EPS=12.52 | Chg30d=+4.35% | Revisions=+50% | GrowthEPS=+1685.2% | GrowthRev=+23.4%
EPS next Year (2027-12-31): EPS=12.67 | Chg30d=+4.90% | Revisions=+50% | GrowthEPS=+1.2% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +61% (up=21, down=4)